3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
164
Phase 1
150
Phase 1/2
84
Phase 3
20
Phase NA
17
Phase EARLY_PHASE1
11
Phase 2/3
4
Phase 4
3
Status
Completed
10
Unknown
5
Terminated
3
Recruiting
3
Not yet recruiting
3
Withdrawn
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
3
Thoracic
1
Conditions
Breast Neoplasms
18
Neoplasms
16
Prostatic Neoplasms
12
Neoplasm Metastasis
10
Pain
9
Colorectal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
8
Polycystic Ovary Syndrome
7
Leiomyoma
6
Anemia
5
Skin Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia
4
Carcinoma, Renal Cell
4
Recurrence
3
Melanoma
3
Liver Neoplasms
3
Kidney Neoplasms
3
Keratosis, Actinic
3
Insulin Resistance
3
Carcinoma, Hepatocellular
3
Cancer Pain
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Interventions
aldesleukin
2
Vemurafenib
1
Ipilimumab
1
Interleukins
1
Interleukin-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
Terminated
×
Melanoma
×
Clear all
NCT03673332
2026-01-22
EPITOP-01
Institut Paoli-Calmettes
Phase 4
Terminated
40 enrolled
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts
NCT01683188
2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4
Terminated
53 enrolled